We compared the frequency of PPM1D mutation in the white blood cells from 1295 ovarian cancer case patients and 834 control subjects. We found a truncating mutation in 20 case patients vs 1 control subject (odds ratio [OR] = 13.07; 95% confidence interval [CI] = 1.75 to 97.55; P < .001). The 12-year mortality of the PPM1D-positive case patients was higher than that of the PPM1D-negative case patients (hazard ratio = 2.02; 95% CI = 1.21 to 3.39; P = .007). Three of the 20 PPM1D carrier case patients had a past history of breast cancer compared with 29 of 1129 noncarriers (OR = 6.69; 95% CI = 1.86 to 24.11; P = .007). The lifetime risks for breast or ovarian cancer among female first-degree relatives of PPM1D mutation carriers were not increased compared with that of case patients without mutations. These observations suggest PPM1D mutations in the mosaic state predispose women to breast and ovarian cancer in the absence of a family history of cancer.
It is estimated that 20% of ovarian cancer cases are due to inherited mutations in dominant susceptibility genes (1) . Genetic testing facilitates the identification of women at high risk of ovarian cancer who are candidates for preventive salpingo-oophorectomy. For example, 13% of women with invasive ovarian cancer carry a BrCA1 or BrCA2 mutation (2) ; 57% of healthy mutation carriers undergo preventive oophorectomy within 2 years of receiving a positive genetic test result (3) and thereby reduce their risk of ovarian cancer by 80% (4) .
recently ruark et al. (5) reported that mutations in the protein phosphatase magnesium-dependent 1 δ (PPM1D) gene confer a 60-fold increase in the risk of ovarian cancer. they found a PPM1D mutation in 12 of 1121 ovarian cancer patients vs 1 in 5861 population control subjects (odds ratio [or] = 63.41; 95% confidence interval [CI] = 8.24 to 488.16; P < .001). PPM1D differs in several ways from the known susceptibility genes. mutations were present in a mosaic state and were detected in DNA from circulating white blood cells but not in DNA from the tumor. All mutations were protein truncating and all were located within the last of six exons of the PPM1D gene.
We wished to confirm the results of ruark et al. and to characterize the pathologic and clinical features of ovarian cancers associated with PPM1D mutations. We sequenced the last exon of the PPM1D gene in 1295 ovarian cancer case patients from the Familial ovarian tumor Study in toronto (2,6) including 146 BrCA1 and BrCA2 mutation carriers and 834 cancerfree control subjects. Case patients were identified through the population-based ontario Cancer registry [described in (6) ]. Control subjects were healthy women with no prior history of cancer who had attended a multimodal screening clinic at Women's College hospital in toronto. the majority of case patients (81%) and control subjects (94%) were white. All participants gave written informed consent. the study was approved by Women's College research Institute's Institutional review Board committee. exon 6 of PPM1D gene (Nm_003620.3) was amplified in four overlapping amplicons. A dual polymerase chain reaction was used for amplifying each amplicon using a set of tagged primers (Supplementary table 1) for the genomic region of interest and a second set of primers to add a unique barcode tag and Illumina adapter to each DNA sample using the tag sequence as an anchor (Fluidigm, San Francisco, CA). the barcoded DNA amplicons for each of the 384 samples were pooled and paired-end sequenced on a single run of a miSeq sequencer (Illumina, San Diego, CA). the BWA (7), GAtK (8) , and SVS (Golden helix, Bozeman, mt) software packages were used for sequence analysis. the mean depth of coverage for the region of interest (PPM1D exon 6) in the 2129 sequenced samples was 11 661-fold. the mean percentage of mutant reads was 16.4% (range = 7.6%-32.5%) among the 21 positive women, suggesting that all mutations were mosaic. All 21 mutations were confirmed by Sanger sequencing. the signal heights corresponding to the mutant alleles were uniformly lower than those for the wild-type alleles, consistent with mosaicism. A t test was used to compare the mean values for continues variables between the two groups, and a χ 2 test was used to compare the frequency distributions of categorical variables. Cox's proportional hazard model was used to evaluate the hazard ratios. the test of proportionality assumption was conducted by the Cox proportional hazard regression model. No substantial violation of the proportionality assumption was found in our data. Curves of probability of survival after diagnosis were estimated by the Kaplan-meier method. the statistical significance level of α equal to 0.05 was used for all tests, and all the P values were two-sided. All statistical analyses were done by SAS software version 9.3 (SAS Institute, Cary, NC).
A PPM1D mutation was seen in 20 of 1295 (1.5%) case patients and one of 834 (0.1%) control subjects (or = 13.07; 95% CI = 1.75 to 97.55; P < .001). None of the 20 PPM1D mutation carriers carried a BrCA1 or BrCA2 mutation. We obtained a DNA sample from the tumor tissue of two of the mutation-positive case BRief COMMuniCatiOn patients, and in neither case patient was the corresponding mutation present in the tumor tissue. the mean age at diagnosis of the 20 PPM1D mutation carriers was 67.8 years (range = 53-79 years), compared with 57.1 years for the 1129 noncarriers (P < .001). the majority (90.0%) of ovarian cancers in PPM1D carriers were serous (table 1); this was statistically significantly higher than the proportion in noncarriers (57.1%; P = .002). Nineteen of the 20 case patients with PPM1D mutations have died, 16 from ovarian cancer and three from other causes (the lone survivor had a mucinous cancer). We compared the survival experience of the 18 serous PPM1D-positive cases with the 647 serous PPM1D-negative cases by Kaplan-meier survival analysis (Figure 1) . the hazard ratio for 12-year ovarian cancer-specific mortality for PPM1D carriers was 2.02 (95% CI = 1.21 to 3.39; P = .007 by log-rank test).
only one of 20 PPM1D mutation carriers had a family history of ovarian cancer (table 1) . the lifetime risks of ovarian or breast cancer among the 54 female firstdegree relatives of 20 PPM1D mutation carriers were not different than the risks among the 3789 female first-degree relatives of the 1129 noncarrier ovarian cancer patients (hr = 1.32; 95% CI = 0.18 to 9.63; P = .78) (Supplementary table 2) . In contrast, the cancer risks among relatives of BrCA1 and BrCA2 mutation carriers were increased three-to nine-fold (Supplementary table 2) . the observation that the risk of ovarian cancer among the relatives of PPM1D mutation carriers is not higher than that in relatives of noncarriers supports the hypothesis that PPM1D mutations are not inherited. three of the 20 ovarian cancer case patients who were PPM1D carriers had a past history of breast cancer, compared with 29 of 1129 noncarriers (or = 6.69; 95% CI = 1.86 to 24.11; P = .007), which supports the hypothesis that PPM1D mutations also predispose to breast cancer (5) .
the basis for the increased risk of cancer in PPM1D mutation carriers is not known. PPM1D gene encodes a type 2C serine/ threonine phosphatase protein. PPM1D was originally found in studies of cell response to ionizing radiation (9) . PPM1D downregulates p53 directly and indirectly through inactivation of p38 mAPK, which is activated in response to stresses such as ultraviolet or ionizing radiation (10) . however, the role of PPM1D protein is not limited to DNA repair regulation; PPM1D also enhances the activities of steroid hormone receptors, including progesterone, estrogen, and androgen receptors (11) .
therefore, PPM1D regulates cell proliferation through both p53 and steroid receptor signaling pathways, and its overexpression has been shown in steroid hormone-driven tumors such as breast (12) , ovarian (13), and prostate cancers (14) . Because all the identified truncating mutations are located in the last exon of PPM1D, it is possible that the transcribed mutated mrNAs escape nonsense-mediated rNA decay and translate to truncated proteins. the truncated PPM1D proteins have an intact phosphatase catalytic domain, which is located at the N-terminal of the protein (15) . It was suggested that inactivation of PPM1D is controlled by phosphorylation of the protein (15, 16) . It is possible that the truncated PPM1D protein lacks the specific amino acids phosphorylated in this process and cannot be inactivated efficiently, resulting in increased activity of PPM1D protein in the cells.
our study is not without limitations. In this study, we confirmed that a PPM1D mutation in circulating white blood cells is associated with an increased risk of epithelial ovarian cancer. It is not known whether this mutation is a cause of cancer or a marker of genetic instability. of note, all patients in our study for whom a mutation had been found had been treated for ovarian cancer and the majority had received platinum therapy. It is Figure 1 . Ovarian cancer-specific survival by PPM1D status. Cox's proportional hazard model was used to evaluate the hazard ratios. Curves of probability of survival after diagnosis were estimated by the Kaplan-Meier method. The number of people at risk in each group of noncarriers (Neg) and PPM1D mutation carriers (PPM1D) are shown on the table below the graph is missing. The cause of death in 15 of the 18 PPM1D carriers with serous ovarian cancer was the cancer; the two others died of other causes.
not clear whether the mutation frequency in the peripheral blood cells is influenced by the genotoxic therapy or whether the PPM1D mutations would be detectable in the blood before the onset of cancer.
the odds ratio of 13 for ovarian cancer corresponds to a lifetime risk of ovarian cancer of 15% to 20%, a level that justifies preventive salpingo-oophorectomy. All 20 PPM1D mutation carriers in our study experienced ovarian cancer after menopause. Approximately 1% of all ovarian cancers might be prevented through screening for PPM1D mutations in healthy women, but given the lack of familial segregation of mutations, identifying carriers eligible for surgical prevention would require population screening of a mutation with a prevalence estimated to be from one in 843 to one in 5681.
